Health economists have put a damper on asthma patients’ hopes for better disease management in 2022.
It’s plagued by incomplete analysis and missing data, yet the Institute for Clinical and Economic Review’s draft evidence report on severe asthma medicine still manages to deliver a familiar refrain. All five of the drugs reviewed, ICER reports, are not cost-effective.
The Institute for Clinical and Economic Review says new medicine for uncontrolled asthma isn’t worth its cost. But its analysis omits key details. View the Graphic. View Social Graphics.